- InTBIR - 2: The second phase of InTBIR
At its inception, InTBIR formed as a pragmatic cooperative consortium of funding agencies from the European Union, the United States, and Canada (InTBIR; Lancet 2012, 2013). The three founding members included the Health Directorate of the European Commons (EC), the NIH’s National Institute of Neurological Disorders and Stroke (NINDS), and the Canadian Institutes of Health Research (CIHR). Subsequently, several affiliated organizational members have joined: One Mind (2015), the U.S Department of Defense (2016), and the Ontario Brain Institute (2017). The first phase of this initiative resulted from governmental organizations using targeted international TBI funding opportunities and relied on the engagement of clinicians and scientists from many public and private institutions throughout its development and implementation. Five years later, the InTBIR initiative has clearly provided important groundwork for the desired international open science ecosystem in clinical TBI research. Now, as the InTBIR initiative transitions to Phase 2, the momentum and successes in data sharing and international coordination of clinical activities will continue; however, the organizational structure will transform from a shared model between funders and principal investigators to a model led primarily by Work Groups of research scientists, clinicians and other key stakeholders. This transformation will maintain collaboration among the stakeholders, including but not limited to the principal investigators and funding organizations, as InTBIR looks to sustain the open science ecosystem that has been established.
The international neurotrauma research community has accepted the challenge posed by this opportunity and set up InTBIR-2, with a new Executive Committee that has wider geographic representation and diversity, and has also established close links with the CONNECT-TBI (http://connect-tbi.med.upenn.edu/) neuropathology network. InTBIR-2 has held two online meetings: [1] A scoping meeting to discuss the future of InTBIR on the 24th of February 2021; and [2] The first InTBIR-2 General Assembly on the 10th of November 2021, where results from the InTBIR studies were presented (presentations are available on https://intbir.incf.org/video-recording-intbir-phase-2-autumn-meeting-available-now). The next InTBIR Scientific Meeting will be held on 16th July 2022 in Berlin, immediately preceding the INTS symposium (https://www.neurotrauma2022.com/).
We welcome new studies and research groups who wish to participate in InTBIR-2.
- Current Executive Committee: These individuals will be responsible for coordinating the activities of InTBIR-2
Mathew Abrams (INCF)
Ramon Diaz-Arrastia (Pennsylvania)
Melinda Fitzgerald (Perth)
Raquel C. Gardner, MD (Primary: San Francisco, USA; Active Collaborations: Israel)
Guoyi Gao (Shanghai)
Peter Hutchinson (Cambridge)
Hester Lingsma (Rotterdam)
Geoff Manley (UCSF)
David Menon (Cambridge)
Fatima Nasrallah (Queensland )
Lindsay Nelson (Wisconsin)
David Oknokwko (Pittsburgh)
Doug Smith (Pennsylvania)
Alexis Turgeon (Quebec)
Cheryl Wellington (Vancouver)
Elisa Zanier (Milan)
- Advisory Committee: In construction – will be finalised early in 2022
- Workgroups – currently under construction, but the provisional list is below, which will be finalised at the next meeting of the Executive Committee early in 2022
[1] Randomised Controlled Trials and Comparative Effectiveness Research
[2] Biosample (blood, CSF, saliva) biomarkers and genetics
[3] Global health
[4] Imaging
[5] Outcomes
[6] Linkage with pre-clinical research
[7] Data science and statistics